Name: Swedish antibody study shows long road to immunity as COVID-19 toll mounts
Brand: reuters.com
SKU: reuters-com-1228
Availability: OnlineOnly

critic

Swedish antibody study shows long road to immunity as COVID-19 toll mounts

preview

By , STOCKHOLM (Reuters) - A Swedish study found that just 7.3 percent of Stockholmers developed COVID-19 antibodies by late April, which could fuel concern that a decision not to lock down Sweden against the pandemic may bring little herd immunity in the near future.The strategy was championed by Chief Epidemiologist Anders Tegnell, whose recommendation for voluntary measures against the virus, rather than a mandatory lockdown like those imposed by many other countries, has divided opinion at home and abroad.Sweden’s strategy of keeping most schools, restaurants, bars and businesses open even as much of Europe hunkered down behind closed doors exposed it to criticism with death rates running far higher than in Nordic neighbours, even if much lower than in countries such as Britain, Italy and France that shut down.The number of COVID-19 patients in intensive care in Sweden has fallen by a third from the peak in late April and health authorities say the outbreak is slowing. However, Sweden has recorded the highest number of COVID-19 deaths per capita in Europe over the last seven days.The antibody study sought to look into the potential for herd immunity, a situation where enough people in a population have developed immunity to an infection to be able to effectively stop that disease from spreading.The findings were roughly in line with models predicting a third of the Swedish capital’s population would have had the virus by now and where at least limited herd immunity could have set in, the Swedish Health Agency said on Wednesday.“It is a little bit lower (than expected) but not remarkably lower, maybe one or a couple of percent,” Tegnell told a Stockholm news conference. “It squares pretty well with the models we have.”However, the herd immunity concept is untested for the novel coronavirus and the extent and duration of immunity among recovered patients is equally uncertain as well.The study drew on some 1,100 tests from across the country although only figures for Stockholm were released.Slideshow While Health Agency officials have stressed herd immunity is not a goal in itself, it has also said the strategy is only to slow the virus enough for health services to cope, not suppress it altogether.They have said that countries employing wholesale lockdowns to prevent any exposure to the coronavirus could face renewed outbreaks as restrictions were eased and be more susceptible to any second wave of the disease.The World Health Organization has warned against pinning hopes on herd immunity. It said last week global studies had found antibodies in only 1-10 percent of the population, results in line with recent findings in Spain and France.“HERD IMMUNITY IS A LONG WAY OFF, IF EVER”Bjorn Olsen, Professor of Infectious Medicine at Uppsala University, is among dozen academics who have criticised Sweden’s pandemic response and labelled herd immunity a “dangerous and unrealistic” approach to dealing with COVID-19.“I think herd immunity is a long way off, if we ever reach it,” he told Reuters after the release of the antibody findings.Sweden’s approach, shaped by a conviction the coronavirus can be slowed but not fully suppressed, is reflected not just in an aversion to quarantines and closures but in a decision to carry out relatively little testing and contact tracing.Tests are largely restricted to hospitalised cases and health care workers. Weekly test numbers still run at less than a third of the government’s goal of 100,000, a far lower per capita rate than Sweden’s Nordic peers and below that of most West European countries.Meanwhile the death toll has continued to rise, compounded by a failure to protect the old and infirm in a country famed for its welfare state.Helen Gluckman, 55, wept bitterly as she related how her 83-year-old father died of a COVID-19 infection contracted in a nursing home after untested patients were admitted there. “We don’t know what will happen when other countries open up, but right now one can’t help but think Sweden has really failed. There are more than 3,000 dead now. That is a horrible number.”With cases having crossed the 30,000 mark, Sweden’s death toll in the pandemic has reached 3,831, more than three times the combined total of Denmark, Norway, Finland and Iceland, all nations with similar welfare systems and demographics.While others locked down to buy time, critics like Olsen say Sweden has done “too little, too late”. They say its laissez-faire approach, also playing down risks posed by asymptomatic spreading of COVID-19, has been catastrophic for the elderly.The government remains adamant that Sweden’s high per capita death toll did not result from the lack of a national lockdown.Defending the strategy, Health and Social Affairs Minister Lena Hellengren said most Swedes had voluntarily minimised their social interactions and movements outside the home. “The Swedes have really changed their behaviour,” she told Reuters.Additional reporting by Andreas Mortensen in Copenhagen; Writing by Niklas Pollard; Editing by Mark HeinrichOur Standards:

By , STOCKHOLM (Reuters) - A Swedish study found that just 7.3 percent of Stockholmers developed COVID-19 antibodies by late April, which could fuel concern that a decision not to lock down Sweden against the pandemic may bring little herd immunity in the near future.The strategy was championed by Chief Epidemiologist Anders Tegnell, whose recommendation for voluntary measures against the virus, rather than a mandatory lockdown like those imposed by many other countries, has divided opinion at home and abroad.Sweden’s strategy of keeping most schools, restaurants, bars and businesses open...

public

Johan Ahlander

Niklas Pollard

Top and breaking news, pictures and videos from Reuters. For more breaking business news, follow @ReutersBiz.

Swedish antibody study shows long road to immunity as COVID-19 toll mounts

No article scores yet.

CRITIC REVIEWS

PUBLIC REVIEWS